We are delighted to announce the following international guests will be joining us in 2020. Further announcements will be made over the coming months. To stay up to date with these announcements please register your interest on the home page of the website.
Robert Bristow Professor - The University of Manchester, United Kingdom
Professor Bristow joined University of Manchester as Director of the Manchester Cancer Research Centre (MCRC) in August 2017 with a remit to developing a new cancer strategy for Manchester with a cancer team science approach. The MCRC is a unique partnership between CRUK, the University of Manchester and the Christie NHS Trust. His primary research interests are in tumour hypoxia, DNA damage signaling and repair in tumours, and the genomics of prostate cancer progression and cancer treatment response. He is particularly interested in novel clinical trials that intensify cancer therapy to prostate cancer patients whose tumours harbor aggressive genetic changes and hypoxic sub-regions.
Professor Bristow is currently a senior group leader in Translational Oncogenomics at the CRUK Manchester Institute and was the lead PI for the Canadian component of the ICGC whole genome prostate cancer sequencing project (CPC-GENE). He has served on a number of senior Scientific Advisory Boards and committees for: Prostate Cancer Foundation (USA), the MOVEMBER Foundation, the American Association for Cancer Research (AACR), the German Cancer Centre, Tuebingen Comprehensive Cancer Centre, NKI Amsterdam, the Danish Cancer Society and sits on the Scientific Executive Board for Cancer Research UK (CRUK). He has over 280 published papers and book chapters and is twice a Canadian Foundation for Innovation (CFI) awardee. He was made a Canadian Cancer Society Research Scientist in 2004, an ESTRO Honorary Fellow in 2011 and a Fellow of the Academy of Sciences (UK) in 2019.
Sigrid Carlsson Dr - Memorial Sloan-Kettering Cancer Center, United States
Dr. Carlsson is a cancer researcher at Memorial Sloan Kettering Cancer Center in New York, USA, with 15 years of prostate cancer research experience and over 100 scientific publications. She is an investigator in the world’s largest randomized study of screening for prostate cancer, the European Randomized Study of Screening for Prostate Cancer. Her work on PSA screening has helped inform national screening guidelines around the world. Dr. Carlsson’s current research aims at finding a better balance between the harms and benefits of prostate-specific antigen (PSA) screening, using multiplex testing and risk-stratified strategies that incorporate clinical information, biomarkers and magnetic resonance imaging. Dr. Carlsson is funded by a career development award from the US National Institutes of Health/National Cancer Institute to study the psychology of decision making to better understand patients’ information needs, which will facilitate the development of better decision aids for cancer screening and lead to improved shared decision.
Scott Eggener Professor - The University of Chicago, United States
Prof Scott Eggener, MD, is an experienced robotic and open surgeon who specializes in the care of patients with prostate, kidney and testicular cancers. His research, which has resulted in over 200 publications, exclusively focuses on urologic cancers and primarily focuses on improving the screening and care of men with prostate cancer. He is the principal investigator of the phase II of the international and multi-institutional trial evaluating MRI-guided Transurethral Ultrasound Ablation (TULSA) system. He is a senior faculty scholar at the Bucksbaum Institute for Clinical Excellence, an associate editor at four medical journals, on the executive board of IVUMed, and frequently participates in volunteer educational and surgical international missions.
Christopher Evans Professor - University of California, Davis, School of Medicine, United States
Prof Evans is professor and chairman of the Department of Urologic Surgery at University of California, Davis School of Medicine and a member of the UC Davis Comprehensive Cancer Center. Prof Evans’ practice is dedicated to the management of patients with urologic malignancies.
His research laboratory focuses on prostate cancer; specifically, mechanisms signalling the androgen receptor to activate prostate cancer growth and progression following castration. His laboratory has developed models to study this and identified novel mechanisms that activate the androgen receptor. His laboratory work tested new agents and brought them from bench studies to animal models to clinical trials.
Prof Evans is former President of the Society of Urologic Oncology. He is an elected member of the American Association of Genitourinary Surgeons. His research laboratory has received funding from the National Institutes of Health, Department of Defense, Prostate Cancer Foundation,
Stand Up To Cancer, New York Academy of Medicine, and the American Cancer Society. He has published over 189 peer-reviewed articles.
Leonard Gomella Professor - Sidney Kimmel Medical College, Thomas Jefferson University, United States
Professor Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at the Sidney Kimmel Medical College and Senior Director for Clinical Affairs for the Sidney Kimmel Cancer Center at Jefferson. Prof Gomella is involved in translational research in the development of new diagnostic techniques and treatments for prostate cancer. His team was first use molecular techniques to detect circulating tumor cells in prostate cancer in 1992 and has been co-chair of the first two international conferences on genetic testing for prostate cancer in 2017 and 2019. He is Urology Chair for NRG (RTOG) and past president of the Society of Urologic Oncology.
David Penson Professor - Vanderbilt University Medical Center, United States
Prof David F. Penson, MD, MPH is the Director of the Center for Surgical Quality and Outcomes Research and Professor and Chair of Urology at Vanderbilt University. His research is focused on the comparative effectiveness in localized prostate cancer and patients’ quality of life. He maintains a clinical practice focused on prostate cancer.
He is the Principal Investigator (PI) of the Prostate Cancer Outcomes Study (PCOS), a large population-based study of prostate cancer survivors funded by the NCI that includes the longest longitudinal patient-reported follow-up in the field. Dr. Penson is also the PI of the CEASAR study, a comparative effectiveness study of surgery vs. radiation for localized prostate cancer, funded by the US Agency for Healthcare Research and Quality (AHRQ) and the Patient-Centered Outcomes Research Institute (PCORI).
James Porter A/Prof - Swedish Medical Center Seattle, United States
A/Prof Porter graduated from the Medical College of Ohio in 1990 and completed his residency in Urology at the University of Washington in 1996. He remained on the faculty at the U.W., where he achieved the rank of Associate Professor. He received his laparoscopic training in Heilbron, Germany, and returned to be the first surgeon in the Northwest to use the laparoscopic approach for radical and donor nephrectomy, partial nephrectomy, retroperitoneal lymph node dissection, and radical prostatectomy.
Before joining Swedish Urology Group in 2005, he served as Chief of Urology at Harborview Medical Center and subsequently as Head of Laparoscopic and Robotic Surgery in the Department of Urology at the University of Washington Medical Center. He has directed the Laparoscopic Fellowship in Urology there and has been active in teaching and promotion of laparoscopic minimally invasive surgical techniques to the regional and national urologic community.
A/Prof Porter is currently the Medical Director for Robotic Surgery at Swedish Medical Center where he also directs the Robotic and Laparoscopic Fellowship in Urology.
Oliver Sartor Professor - Tulane Medical Center, United States
Professor Oliver Sartor is an internationally recognized expert in prostate cancer currently Medical Director at Tulane Cancer Center, United States. His medical practice and research have focused on prostate cancer since 1990 when he finished a medical oncology fellowship at the National Cancer Institute (NCI). He has published over 400 articles and book chapters and led multiple national and international clinical trials as either a principal investigator or co-principal investigator. In particular he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel.
He has published approximately 400 scientific articles and has given hundreds of invited lectures on advanced prostate cancer in 33 countries through the years.
Derya Tilki Professor - Martini-Klinik Prostate Cancer Center and University Hospital, Hamburg, Germany
Derya Tilki is Professor of Urology at the Martini-Klinik Prostate Cancer Center in Hamburg, Germany. Professor Tilki received her urologic residency training in Munich, with research fellowships at Harvard Medical School in Boston and Weill Cornell Medical Center in New York. She completed a urooncology fellowship at UC Davis in Sacramento.